Achieve Life Sciences Inc. - Common ...

ACHV

2.89

+0.40

+16.1%

Please Login or Register

Login|Register FREE

Please Login or Register

Login|Register FREE

About ACHV

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Primary Exchange: NASDAQ
SIC In Vitro & In Vivo Diagnostic Substances
NAICS In-Vitro Diagnostic Substance Manufacturing

ACHV is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 16.1 B 1.60928E+10 3,416 3416 0.0% 0 5 K 4846
WMCR Invesco Wilshire Micro-Cap ETF 30.1 M 3.01E+07 991 991 0.01% 0.0001 3 K 2903

Wait, Before You Leave...